制药合作伙伴默克和Moderna周四宣布，在一项晚期临床试验中，针对黑色素瘤（最致命的皮肤癌）的个性化mRNA疫苗与标准治疗相比，将死亡或复发的风险降低了42%。
Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical partners Merck and Moderna announced Thursday.
这些结果是黑色素瘤治疗的一项重大进展；默克和Moderna已在与监管机构接洽，以获批该疫苗。更广泛地说，该疫苗的成功增强了人们的希望，即mRNA疫苗和个性化靶向癌症药物为癌症疗法提供了一种新范式。
The results are a significant advance in melanoma treatment; Merck and Moderna are already engaging with regulatory authorities to get the vaccine approved. More broadly, the vaccine's success bolsters hope that mRNA vaccines and individualized cancer-targeting medicines offer a new paradigm for cancer therapies.
Moderna首席执行官Stéphane Bancel在声明中说：“从一开始，我们就相信mRNA技术能够开发出专门针对每位患者肿瘤的癌症治疗方法。”他表示，试验结果“标志着这一愿景的决定性时刻，并展示了当我们重新思考药物制造方式时能够实现什么。”这也“强化了我们的信念，即mRNA有潜力从根本上改变我们治疗癌症的方式。”
"From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient’s tumor," Moderna CEO Stéphane Bancel said in a statement. The trial results "mark a defining moment for that vision and show what’s possible when we rethink how medicines are made." They also "reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer," he said.